Strides Pharma Reaches 9 US OTCs With Naproxen
OTC NDA Approvals Continue As Launch Date Nears For FDA’s Overhauled Monograph Program
Executive Summary
Recent approval of Indian firm’s ANDA for 220-mg naproxen capsules comes as NDA process for launching OTCs in US soon could take a back seat to overhauled monograph program the pharma industry prepares to start using on 1 October.